Moonseong Heo,Brianna L. Norton,Irene Pericot-Valverde,Shruti H. Mehta,Judith I. Tsui,Lynn E. Taylor,Paula J. Lum,Judith Feinberg,Arthur Y. Kim,Julia Arnsten,Sophie Sprecht-Walsh,Kimberly Page,Alain H. Litwin,the HERO Study Group,Alain H. Litwin,Moonseong Heo,Irene Pericot-Valverde,Hagan Walker,Ashley Coleman,Shruti H. Mehta,Courtney Borsuk,Brian Dickerson,Oluwaseun Falade-Nwulia,Michael Fingerhood,Taryn Haselhuhn,Angela Mason,Juhi Moon,Yngvild Olsen,Vickie Walters,Arthur Y. Kim,Jillian M. Roche,William Schmitt,Virginia Lijewski,Anita Pitts,Syeda Raji,Taniya Silva,Fiona Evans,Hope Koene,Joelle Brown,Brianna Norton,Linda Agyemang,Julia Arnsten,Alison Karasz,Paul Meissner,Kiara Lora,Jennifer Hidalgo,Irene Soloway,Karen Jefferson,Joyce Wong,Andrea Kermack,Melissa Stein,Gilian Joseph,Karyn London,Lincoln Allen,Venecia Marte,Tatiana Vera,Romy Alvarez,M. Diane Mckee,Paula J. Lum,Ellen S. Stein,Anne F. Luetkemeyer,Caycee Cullen,Gurjot Gill,Hannah Tierney,Scott Shapiro,Soraya Azari,Joanna Eveland,Daniel Berrner,Pauli Grey,Jordan Akerley,Kimberly Page,Katherine Wagner,Herbert Davis,Cristina Murray-Krezan,Vanessa Jacobsohn,Jessica Anderson,Lynn E. Taylor,Karen Tashima,Sophie Sprecht-Walsh,Aurielle Thomas,Melissa Hordes,Danielle McGregor,Patrick Duryea,Kathryn Weenig,Judith I. Tsui,Kendra L. Blalock,Hyang Nina Kim,Meena S. Ramchandani,Jocelyn R. James,K. Michelle Peavy,Paul Grekin,Michael Ninburg,Judith Feinberg,Samuel Wilkinson,Danielle Thomas,Lacey Kelley,Andrea Calkins,Gabrielle Henry,Stakeholder Advisory Board,Alice Ashler,Eyasu Teshale,Sebastian Seiguer,Lauren Brown,Katrina Rios,James Spellman,Daniel Raymond,Susan Beane,Ronni Marks,Tracy Swan,Chuck Walworth,Yolanda Lie,Jackie Reeves,Walter P. Ginter,Jules Devin,Ryan Clary,Tina Broder,Bekeela Davila,Nirah Johnson,Umaima Khatun,Colleen Flanigan,Ray Ahmed,Bob Polluck,Serene Mastrianni,James Morton,Emily Baldwin,Rick Pesano,Charissa Fotinos,Douglas Fish,James Becker,John W. Ward,Mark Parrino,Carleen Maxwell

Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Direct-acting antivirals (DAAs) are highly effective for treating HCV infection even among people who inject drugs (PWID). Yet, little is known about patients' adherence patterns and their association with sustained virologic response (SVR) rates. We aimed to summarize various adherence patterns and determine their associations with SVR.</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">Electronic blister packs were used to measure daily adherence to once-a-day sofosbuvir/velpatasvir during the 12-week treatment period among active PWIDs. Blister pack data were available for 496 participants who initiated DAAs for whom SVR status was known. Adherence was summarized in multiple patterns, such as total adherent days, consecutive missed days, and early discontinuations. Thresholds for adherence patterns associated with &gt;90% SVR rates were also determined.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall SVR rate was 92.7%, with a median adherence rate of 75%. All adherence patterns indicating greater adherence were significantly associated with achieving SVR. Participant groups with ≥50% (&gt;42/84) adherent days or &lt;26 consecutive missed days achieved an SVR rate of &gt;90%. Greater total adherent days during 9-12 weeks and no early discontinuation were significantly associated with higher SVR rates only in those with &lt;50% adherence. Participants with first month discontinuation and ≥2 weeks of treatment interruption had low SVR rates, 25% and 85%, respectively. However, greater adherent days were significantly associated with SVR (adjusted odds ratio 1.10; 95% CI 1.04-1.16; p &lt;0.001) even among participants with ≥14 consecutive missed days.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High SVR rates can be achieved in the PWID population despite suboptimal adherence. Encouraging patients to take as much medication as possible, with &lt;2 weeks consecutive missed days and without early discontinuation, was found to be important for achieving SVR.</AbstractText>IMPACT AND IMPLICATIONS: <AbstractText Label="IMPACT AND IMPLICATIONS" NlmCategory="UNASSIGNED">People who inject drugs can be cured of HCV in &gt;90% of cases, even with relatively low adherence to direct-acting antivirals, but early discontinuations and long treatment interruptions can significantly reduce the likelihood of achieving cure. Clinicians should encourage people who inject drugs who are living with HCV to adhere daily to direct-acting antivirals as consistently as possible, but if any days are interrupted, to continue and complete treatment. These results from the HERO study are important for patients living with HCV, clinicians, experts writing clinical guidelines, and payers.</AbstractText>CLINICAL TRIAL NUMBER: <AbstractText Label="CLINICAL TRIAL NUMBER" NlmCategory="BACKGROUND">NCT02824640.</AbstractText>

Overreporting of adherence to hepatitis C direct-acting antiviral therapy and sustained virologic response among people who inject drugs in the HERO study

Injecting practices during and after hepatitis C treatment and associations with not achieving cure among persons who inject drugs

Optimal Hepatitis C Treatment Adherence Patterns and Sustained Virologic Response. among People Who Inject Drugs: The HERO Study

HCV direct-acting antiviral therapy adherence in people who inject drugs

Distrust in the Health Care System and Adherence to Direct-Acting Antiviral Therapy among People with Hepatitis C Virus Who Inject Drugs

Variability of Hepatitis C Treatment Cascade Outcomes among People Who Inject Drugs across Geographically Diverse Clinics in the US: The HERO Study

Hazardous Alcohol Use and Its Effect on Direct-Acting Antiviral Therapy Initiation among People with Active Injection Drug Use and Current Hepatitis C Infection

Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010–2018

HCV‐HIV co‐infection in people who inject drugs: Barriers to treatment and cure of HCV infection in the era of DAAs, a prospective study in Athens, Greece

917. Accessible HCV Care for People Who Inject Drugs: Randomized Clinical Trial Comparing Low-Threshold Treatment at a Syringe Service Program Versus Facilitated Referral

Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C

Impact of Hepatitis C Treatment Uptake on Cirrhosis and Mortality in Persons Who Inject Drugs : A Longitudinal, Community-Based Cohort Study

Harm Reduction in Peer-Assisted Telemedicine for Hepatitis C: Secondary Outcomes of a Randomized Controlled Trial

Real-life data of hepatitis C treatment with direct acting antiviral therapy in persons injecting drugs or on opioid substitution therapy

Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs

Adherence in HCV Treatment: What We Know

An Analysis of Social Determinants of Health and Their Implications for Hepatitis C Virus Treatment in People Who Inject Drugs: The Case of Baltimore

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment

Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era

Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City

Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial